Familial pituitary tumor syndromes

Endocrine Practice

Volumn 17, Issue SUPPL. 3, 2011, Pages 41-46

  Vasilev, Vladimir ^a,b   Daly, Adrian F ^a   Petrossians, Patrick ^a   Zacharieva, Sabina ^b   Beckers, Albert ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGENESIS; CARNEY COMPLEX; CLINICAL FEATURE; EARLY DIAGNOSIS; FAMILIAL DISEASE; FAMILIAL ISOLATED PITUITARY ADENOMA; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 4; REVIEW;

CARNEY COMPLEX; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PITUITARY NEOPLASMS;

EID: 84860403253     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11064.RA     Document Type: Review

References (48)

1. Davis JR, Farrell WE, Clayton RN. Pituitary tumours. Reproduction. 2001;121:363-371. (Pubitemid 32243680)
2. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101: 613-619. (Pubitemid 38970613)
3. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91: 4769-4775. (Pubitemid 44917305)
4. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72:377-382.
5. Daly AF, Jaffrain-Rea ML, Ciccarelli A, et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab. 2006;91:3316-3323. (Pubitemid 44402097)
6. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med. 1954;16:363-371.
7. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658-5671. (Pubitemid 33152604)
8. Falchetti A, Marini F, Luzi E, Tonelli F, Brandi ML. Multiple endocrine neoplasms [published correction appears in Best Pract Res Clin Rheumatol. 2008;22:III.]
9. Best Pract Res Clin Rheumatol. 2008;22:149-163.
10. Marini F, Falchetti A, Del Monte F, et al. Multiple endocrine neoplasia type 1. Orphanet J Rare Dis. 2006;1:38.
11. Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA Jr, Norton JA. Lethality of multiple endocrine neoplasia type I [with discussion]. World J Surg. 1998; 22:581-587. (Pubitemid 28215436)
12. Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23:543-554.
13. Scheithauer BW, Laws ER Jr, Kovacs K, Horvath E, Randall RV, Carney JA. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin Diagn Pathol. 1987;4:205-211.
14. Vergès B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002; 87:457-465. (Pubitemid 34158204)
15. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjöld M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature. 1988;332:85-87. (Pubitemid 18083554)
16. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neo-plasia-type 1. Science. 1997;276:404-407.
17. Namihira H, Sato M, Murao K, et al. The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promoter activity. J Mol Endocrinol. 2002; 29:297-304. (Pubitemid 36024546)
18. Scacheri PC, Davis S, Odom DT, et al. Genome-wide analysis of menin binding provides insights into MEN1 tu-morigenesis. PLoS Genet. 2006;2:e51.
19. Hughes CM, Rozenblatt-Rosen O, Milne TA, et al. Menin associates with a trithorax family histone methyl-transferase complex and with the hoxc8 locus. Mol Cell. 2004;13:587-597. (Pubitemid 38299385)
20. Hendy GN, Kaji H, Sowa H, Lebrun JJ, Canaff L. Menin and TGF-beta superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast. Horm Metab Res. 2005;37:375-379. (Pubitemid 41008772)
21. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the frst decade following identifcation of the gene. Hum Mutat. 2008;29:22-32.
22. Olufemi SE, Green JS, Manickam P, et al. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Hum Mutat. 1998;11: 264-269. (Pubitemid 28177866)
23. Burgess JR, Shepherd JJ, Parameswaran V, Hoffman L, Greenaway TM. Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance pattern. J Clin Endocrinol Metab. 1996;81: 1841-1845. (Pubitemid 26152473)
24. Georgitsi M. MEN-4 and other multiple endocrine neopla-sias due to cyclin-dependent kinase inhibitors (p27[Kip1] and p18[INK4C]) mutations. Best Pract Res Clin Endocrinol Metab. 2010;24:425-437.
25. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans [published correction appears in Proc Natl Acad Sci USA. 2006;103:19213].
26. Proc Natl Acad Sci USA. 2006;103: 15558-15563.
27. Georgitsi M, Raitila A, Karhu A, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neopla-sia. J Clin Endocrinol Metab. 2007;92:3321-3325. (Pubitemid 47236408)
28. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states [published correction appears in J Clin Endocrinol Metab. 2009;94:2674].
29. J Clin Endocrinol Metab. 2009;94:1826-1834.
30. Carney JA, Hruska LS, Beauchamp GD, Gordon H. Dominant inheritance of the complex of myxomas, spotty pigmentation, and endocrine overactivity. Mayo Clin Proc. 1986;61:165-172. (Pubitemid 16082927)
31. Boikos SA, Stratakis CA. Carney complex: the frst 20 years. Curr Opin Oncol. 2007;19:24-29.
32. Kirschner LS. PRKAR1A and the evolution of pituitary tumors. Mol Cell Endocrinol. 2010;326:3-7.
33. Verloes A, Stevenaert A, Teh BT, Petrossians P, Beckers A. Familial acromegaly: case report and review of the literature. Pituitary. 1999;1:273-277.
34. Valdes Socin H, Poncin J, Stevens V, Stevenaert A, Beckers A. Adenomes hypophysaires familiaux isoles non lies avec la mutation somatique NEM-1: suivi de 27 patients. Ann Endocrinol (Paris). 2000;61:301.
35. Beckers A. Familial isolated pituitary adenomas. In: The Ninth International Workshop on Multiple Endocrine Neoplasia (MEN2004). J Intern Med. 2004;255:696-730.
36. Chahal HS, Chapple JP, Frohman LA, Grossman AB, Korbonits M. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab. 2010;21:419-427.
37. Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol. 2007;157:371-382. (Pubitemid 350018439)
38. Leontiou CA, Gueorguiev M, van der Spuy J, et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab. 2008;93:2390-2401. (Pubitemid 351831563)
39. Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312:1228-1230. (Pubitemid 43801151)
40. Daly AF, Vanbellinghen JF, Khoo SK, et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab. 2007;92:1891-1896. (Pubitemid 46997206)
41. Daly AF, Tichomirowa MA, Petrossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95:E373-E383.
42. Carver LA, LaPres JJ, Jain S, Dunham EE, Bradfeld CA. Characterization of the Ah receptor-associated protein, ARA9. J Biol Chem. 1998;273:33580-33587. (Pubitemid 29005744)
43. Jaffrain-Rea ML, Angelini M, Gargano D, et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer. 2009;16: 1029-1043.
44. Bolger GB, Peden AH, Steele MR, et al. Attenuation of the activity of the cAMP-specifc phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem. 2003;278:33351-33363. (Pubitemid 37055787)
45. de Oliveira SK, Hoffmeister M, Gambaryan S, Müller-Esterl W, Guimaraes JA, Smolenski AP. Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J Biol Chem. 2007;282: 13656-13663. (Pubitemid 47100556)
46. Ozfrat Z, Korbonits M. AIP gene and familial isolated pituitary adenomas. Mol Cell Endocrinol. 2010;326:71-79.
47. Vargiolu M, Fusco D, Kurelac I, et al. The tyrosine ki-nase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability. J Clin Endocrinol Metab. 2009;94:2571-2578.
48. Cazabat L, Guillaud-Bataille M, Bertherat J, Raffn-Sanson ML. Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas. Horm Res. 2009;71:132-141.